Samer Choucair: The Future of Pharmaceutical Investment Depends on Therapeutic Platforms
Entrepreneur Samer Choucair said the rapid expansion of GLP-1 medicines into the treatment of health conditions beyond obesity and diabetes represents a fundamental transformation in the global pharmaceutical industry.
He noted that recent clinical findings concerning the use of semaglutide in alcohol-use disorders are strengthening investor interest in companies that possess versatile therapeutic platforms capable of opening new markets.
Samer Choucair explained that the GLP-1 market is undergoing a broad reassessment following the emergence of scientific data linking this class of treatments to effects extending beyond blood-sugar control and weight reduction.
These potential benefits include pathways associated with health-related behaviour and the brain’s reward systems, creating new investment opportunities for pharmaceutical companies and reshaping institutional capital-allocation priorities across the healthcare sector.
He noted that a recent Phase II clinical trial found that oral semaglutide, the active ingredient in several well-known diabetes and obesity medicines, helped reduce heavy-drinking days and alcohol cravings among adults with alcohol-use disorder.
Choucair emphasized that these findings form part of a wider series of developments expanding the investment case for this pharmaceutical category, positioning GLP-1 medicines as therapeutic platforms rather than products associated with a single medical indication.
He added that the current transformation in the pharmaceutical industry reflects a shift away from investment focused on single-purpose treatments toward assets capable of addressing multiple disease pathways, particularly where those conditions share common biological mechanisms, such as the brain-reward systems associated with obesity and addiction.
Samer Choucair explained that global markets are beginning to reprice pharmaceutical companies according to their ability to expand the therapeutic applications of existing assets, rather than merely assessing the current market size of an individual product.
Institutional investors favour companies with multiple growth opportunities because they reduce dependence on a single drug lifecycle and can provide stronger risk-adjusted returns over the long term.
“GLP-1 platforms are no longer assets associated with a single therapeutic indication, but have become capital assets capable of substantially expanding their addressable markets,” Samer Choucair said. “Investors are seeking companies that can demonstrate their assets’ ability to cross traditional therapeutic boundaries.”
He noted that alcohol-use disorder represents one of the world’s most significant health and economic challenges, affecting millions of people and generating substantial social and healthcare costs.
The limited range of pharmaceutical options currently available makes any treatment with a well-established safety profile and an innovative mechanism of action an important medical and investment opportunity.
Choucair emphasized that the mechanism of GLP-1 medicines extends beyond effects involving the digestive system to areas of the brain responsible for dopamine and reward.
This helps explain the growing interest in their potential use across additional therapeutic fields associated with behaviour and addiction, including other disorders that remain under investigation.
He explained that the potential expansion of therapeutic indications creates an opportunity to redistribute capital within the pharmaceutical sector.
Investment funds and asset managers are directing greater attention toward companies with research platforms capable of producing multiple therapeutic applications rather than businesses dependent on a single medicine or market.
Samer Choucair noted that Novo Nordisk holds a leading position in the market for the various forms of semaglutide, while Eli Lilly continues strengthening its position through the development of tirzepatide and other therapeutic programmes.
Competition among major pharmaceutical companies is expected to accelerate clinical trials and broaden research across obesity, diabetes, addiction, and related medical conditions.
He added that the GLP-1 market is positioned for further growth during the coming years, supported by the expansion of therapeutic applications and rising global demand.
Regulatory approval for new indications could add substantial value to the companies that own these platforms.
Samer Choucair explained that institutional investors view early clinical data as an opportunity to reassess assets before the market has fully incorporated their potential value.
Companies with clearly defined development programmes in new therapeutic fields may therefore offer important opportunities for long-term investment funds.
“Markets frequently delay pricing the expansion of therapeutic indications until Phase III data or regulatory approvals become available,” Choucair said. “This delay can create valuation gaps that institutional investors with a long-term perspective are well positioned to capture.”
He noted that pharmaceutical investment during the coming phase will increasingly focus on assets combining large markets, such as obesity and diabetes, with specialized, high-margin fields such as addiction treatment, particularly where current competition remains limited.
Samer Choucair emphasized that the sector also faces several challenges, including pricing and insurance-coverage pressures, increasing competition from new oral formulations and dual-action compounds, and supply-chain constraints.
Building successful investment positions will require considerable selectivity and a detailed understanding of each company’s competitive capabilities.
He explained that future opportunities include expanding the number of patients who can benefit from these treatments, improving adherence through the development of oral formulations, and reducing the healthcare and social costs associated with chronic diseases and behavioural disorders.
Choucair added that Gulf economies are following these developments closely because of the high prevalence of obesity and diabetes and the need to strengthen healthcare innovation.
The expansion of GLP-1 applications could create opportunities for research collaboration and investment in domestic pharmaceutical manufacturing as part of broader efforts to support healthcare and innovation.
However, the direct relevance of alcohol-use-disorder treatments in the region is likely to remain limited because of cultural and social considerations.
Samer Choucair noted that the coming phase will bring a clearer distinction between companies with a genuine ability to influence the brain’s reward systems and develop multipurpose treatments and those whose products remain confined to conventional indications.
“Investors who build positions around versatile therapeutic platforms rather than individual products will be better placed to benefit from the next growth cycle in the pharmaceutical sector,” Samer Choucair said.
Concluding his remarks, entrepreneur Samer Choucair emphasized that the transformation of the GLP-1 category represents a transition from conventional metabolic medicines toward a new generation of treatments capable of influencing health-related behaviour and reward systems.
He said this transformation will have a clear effect on institutional investment flows and pharmaceutical-company valuations during the coming years.